Opinion|Videos|January 9, 2024
Identifying the Right CDMO to Support Biopharma Manufacturing
Author(s)Ascendia Pharma
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals, highlights traits that a (bio)pharmaceutical company look for when identifying a CDMO to support drug development and manufacturing programs.
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals discusses:
- What to look for when identifying a CDMO for a drug development project
- Ascendia Pharmaceuticals and its expansion of manufacturing services
- Ascendia Pharmaceuticals as a "Partner of Choice"
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)
Trending on Pharmaceutical Technology
1
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
2
AAPS PharmSci 360 2025: Trends in Bioanalysis
3
PharmTech Weekly News Roundup – Week of November 3, 2025
4
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
5
